AMERICAN SOCIETY OF HEMATOLOGY

BUD · Budget/Appropriations

Public health program funding Federal research funding Advanced Research Projects Agency for Health (ARPA-H) FY 2025 and FY 2026 NIH funding FY 2025 and FY 2026 AHRQ funding FY 2025 and FY 2026 CDC funding FY 2025 and FY 2026 funding for CDC Sickle Cell Data Collection program FY 2025 and FY 2026 funding for HRSA Sickle Cell Disease Treatment Demonstration program and Sickle Cell Disease Newborn Screening program FY 2025 and FY 2026 funding for Defense Health Research Programs, including the Congressionally Directed Medical Research Programs (CDMRP) Impact of restructuring and reorganization of federal public health and research agencies FY2025 Full-Year Continuing Appropriations and Extensions Act (through 9/30/2025) (H.R. 1968) FY2025 Budget Resolution (H. Con. Res. 14/S. Con. Res. 7)

Literal federal measure citations: H.R. 1968, H. Con. Res. 14, S. Con. Res. 7

MED · Medical/Disease Research/Clinical Labs

Sickle cell disease/trait issues Hematology/oncology treatment issues Hematology/oncology drug research and approval issues General hematology public health and research issues Open access policy for peer reviewed research journals Women's health and research Issues impacting blood supply shortages/safety Issues impacting delivery of bone marrow, peripheral blood, and cord blood Clinical trials regulations and coverage Issues impacting laboratory testing and pediatric reference intervals (PRIs) Issues impacting laboratory developed tests (LDTs) Issues impacting drug shortages FDA guidance impacting hematology Impact of restructuring and reorganization of federal public health and research agencies

MMM · Medicare/Medicaid

Coverage of blood transfusions under Medicare Hospice Benefit Medicare physician reimbursement issues Issues related to CAR-T/cellular and gene therapies Implementation of the Medicare Access and CHIP Reauthorization Act of 2015 (P.L. 114-10) Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) CMS national coverage determinations Medicaid coverage for sickle cell disease Issues related to telemedicine/telehealth Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) dental coverage for Medicare beneficiaries National Coverage Decision for hematopoietic stem cell transplantation (HSCT) for MDS Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Sickle cell disease quality measures Issues impacting drug shortages Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Impact of proposed Medicaid funding cuts on hematology FY2025 Budget Resolution (H. Con. Res. 14/S. Con. Res. 7) Sickle Cell Disease Comprehensive Care Act (S. 721)

Literal federal measure citations: H.R. 879, H. Con. Res. 14, S. Con. Res. 7, S. 721

HCR · Health Issues

Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting blood supply shortages/safety Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and abortion access Born-Alive Abortion Survivors Protection Act (H.R. 21/S. 6) Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Impact of restructuring and reorganization of federal public health and research agencies Sickle Cell Disease Comprehensive Care Act (S. 721)

Literal federal measure citations: H.R. 21, S. 6, S. 721